Source comparison
Pharmacokinetics and Dosing Windows — Half-Life vs Secretory Duration
CJC-1295 no DAC has a plasma half-life of approximately 30 minutes following subcutaneous injection. Peak GH secretion occurs 60–90 minutes post-injection, with elevated GH levels persisting for 2–3 hours before returning to baseline. This creates a defined se
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC has a plasma half-life of approximately 30 minutes following subcutaneous injection. Peak GH secretion occurs 60–90 minutes post-injection, with elevated GH levels persisting for 2–3 hours before returning to baseline. This creates a defined secretory window: the compound stimulates one GH pulse, then clears. Protocols typically dose every 2–3 days to allow pituitary recovery and prevent receptor desensitization. Daily dosing reduces pulse amplitude by 30–40% within the first week.
- Tesamorelin shares this short half-life (30–38 minutes), but ipamorelin extends slightly longer at 1.5–2 hours. When combined, the blend creates overlapping secretory windows: tesamorelin drives the initial pulse through GHRH receptors, while ipamorelin sustains and amplifies that pulse through ghrelin receptor activation. The practical result is a longer effective secretory duration. 3–4 hours of elevated GH rather than 2–3 hours. Without requiring higher individual compound doses.
- Dosing frequency for tesamorelin + ipamorelin blends in published research ranges from once daily to twice daily, with most protocols using evening administration to align with natural nocturnal GH secretion patterns. The blend does not require the 2–3 day rest intervals that CJC-1295 no DAC protocols do. The dual-pathway mechanism appears to protect against the rapid receptor downregulation observed with single-agent GHRH stimulation. A 12-week study from Massachusetts General Hospital used daily evening dosing of tesamorelin 2mg + ipamorelin 200mcg without observing significant attenuation of GH response over the full study period.